Breyanzi Approved for Adults With Relapsed/Refractory CLL or SLL

The FDA granted accelerated approval of Breyanzi for the treatment of adult patients with relapsed/refractory CLL ...

MARCH 20, 2024

Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CLL is a lymphoproliferative disorder characterized by the accumulation of circulating mature B cells that are ...

MARCH 20, 2024

Supportive Care and Other Tools for Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In patients who have received previous chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-directed ...

AUGUST 29, 2023

Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CLL and SLL are different manifestations of the same underlying disease process.

MAY 24, 2023

Study Identifies Cardiovascular Toxicities Associated With Ibrutinib

The study identified several cardiovascular toxicities associated with ibrutinib, including supraventricular ...

SEPTEMBER 26, 2019

FDA Approves Imbruvica With Gazyva for First-Line CLL Treatment

The FDA expanded the labeling for Imbruvicato include use with Gazyva in treatment-naive patients with chronic ...

FEBRUARY 4, 2019

FDA Approves Copiktra for Relapsed or Refractory CLL, SLL

Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of ...

SEPTEMBER 25, 2018

Venclexta Approved for CLL/SLL After 1 Prior Therapy

The FDA granted regular approval to venetoclax in patients with chronic lymphocytic leukemia (CLL) or small ...

JUNE 18, 2018

Rituxan Hycela Approved for FL, DLBCL, CLL

Rituximab and hyaluronidase human (Rituxan Hycela,  Genentech) was approved for subcutaneous injection for the ...

JUNE 23, 2017